Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 673-688

  Mackey, John R ^a   Kerbel, Robert S ^b   Gelmon, Karen A ^c   McLeod, Deanna M ^d   Chia, Stephen K ^c   Rayson, Daniel ^e   Verma, Sunil ^f   Collins, Loretta L ^d   Paterson, Alexander H G ^g   Robidoux, André ^h   Pritchard, Kathleen I ^f  

^a CROSS CANCER INSTITUTE   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Kaleidoscope Strategic   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^g TOM BAKER CANCER CENTRE   (Canada)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiogenesis inhibitors; Antineoplastic agents; Antineoplastic combined chemotherapy protocols; Breast neoplasms; Controlled clinical trial as topic; Vascular endothelial growth factor antagonists and inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; AXITINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LAPATINIB; LETROZOLE; MOTESANIB; NAVELBINE; PACLITAXEL; PAZOPANIB; PROTEIN KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN ISCHEMIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARDIOTOXICITY; CHOLECYSTITIS; CHOLESTASIS; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; GALLBLADDER DISEASE; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INFECTION; JAUNDICE; LIVER DYSFUNCTION; LIVER FAILURE; LOW DRUG DOSE; META ANALYSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL VEIN THROMBOSIS; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84861657446     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.002     Document Type: Review

References (110)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
2. Kerbel R.S. Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
3. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400.
4. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
5. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
6. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
7. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
8. Brem S.S., Gullino P.M., Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977, 195:880-882.
9. Jensen H.M., Chen I., DeVault M.R., Lewis A.E. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982, 218:293-295.
10. McLeskey S.W., Tobias C.A., Vezza P.R., Filie A.C., Kern F.G., Hanfelt J. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 1998, 153:1993-2006.
11. Weinstat-Saslow D.L., Zabrenetzky V.S., VanHoutte K., Frazier W.A., Roberts D.D., Steeg P.S. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994, 54:6504-6511.
12. Fox S.B., Leek R.D., Bliss J., et al. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997, 89:1044-1049.
13. Weidner N., Folkman J., Pozza F., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992, 84:1875-1887.
14. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1-8.
15. Hansen S., Grabau D.A., Sorensen F.B., Bak M., Vach W., Rose C. The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 2000, 6:139-146.
16. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
17. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30:117-124.
18. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
19. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
20. Miles D.W., Chan A., Dirix L.Y., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
21. Gray R., Bhattacharya S., Bowden C., Miller K., Comis R.L. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009, 27:4966-4972.
22. Brufsky A., Bondarenko I.N., Smirnov V., et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab In combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009, 69(Suppl.):24. [Abstr 42].
23. Brufsky A., Rivera R.R., Hurvitz S.A., et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2010, 28(Suppl.):15s. [Abstr 1021].
24. Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011, 29:632-638.
25. Yardley D.A., Hart L., Waterhouse D.M., et al. Preliminary safety results: addition of bevacizumab to 3 docetaxel regimens as adjuvant therapy for early stage breast cancer. Cancer Res 2009, 69(Suppl.):2. [Abstr 4107].
26. Wildiers H., Fontaine C., Vuylsteke P., et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010, 123:463-469.
27. Barrios C.H., Liu M.C., Lee S.C., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131.
28. Mayer E.L., Dhakil S., Patel T., et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010, 21:2370-2376.
29. Crown J., Dieras V., Staroslawska E., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010, 28(Suppl.):18. [Abstr LBA1011].
30. Bergh J., Greil R., Voytko N., et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010, 28(Suppl.):18. [Abstr LBA1010].
31. Robert N.J., Saleh M.N., Paul D., et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin breast cancer 2011, 11:82-92.
32. Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
33. Moreno-Aspitia A., Morton R.F., Hillman D.W., et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009, 27:11-15.
34. Bianchi G., Loibl S., Zamagni C., et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009, 20:616-624.
35. Gomez P., Roche H., Costa F., et al. Overall Survival Data from SOLTI-0701: A Multinational, Double-Blind, Placebo-Controlled, Randomized Phase 2b Study Evaluating the Oral Combination of Sorafenib and Capecitabine in Patients with Locally Advanced or Metastatic HER2-Negative Breast Cancer. Cancer Res 2010, 70(Suppl.):24. [Abstr P2-16-01].
36. Hudis C., Tauer K.W., Hermann R.C., et al. Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). J Clin Oncol 2011, 29(Suppl.). [Abstr 1009].
37. Bondarde S., Kaklamani V., Prasad Sahoo T., et al. Sorafenib in Combination with Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer: Overall Survival Results from a Double-Blind, Randomized, Placebo-Controlled, Phase 2b Trial. Cancer Res 2011, 70(Suppl.):24. [Abstr P2-16-03].
38. Gradishar W.J., Dalenc F., Kaklamani V.G., et al. Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). J Clin Oncol 2010, 28(Suppl.):15s. [Abstr 1073].
39. Slamon D., Gomez H.L., Kabbinavar F.F., et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008, 26(Suppl.):15s. [Abstr 1016].
40. Rugo H.S., Stopeck A.T., Joy A.A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29:2459-2465.
41. Taylor S.K., Chia S., Dent S., et al. A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist 2010, 15:810-818.
42. Martin M., Roche H., Pinter T., et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011, 12:369-376.
43. Boer K., Lang I., Llombart-Cussac A., et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs 2010.
44. Hyams D.M., de Oliveira C., Snyder R., et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: A phase II randomized study. Cancer Res 2009, 69(Suppl.):24. [Abstr 204].
45. Hurvitz S.A., Bosserman L.D., Leland-Jones B., et al. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or stage III breast cancer. J Clin Oncol 2008, 26(Suppl.):15s. [Abstr 562].
46. von Minckwitz G., Bauerfeind I., Gerber B., et al. Geparquinto: First planned safety analysis on 60 patients with HER2 negative primary breast cancer receiving neoadjuvant chemotherapy +/- bevacizumab or +/- RAD001 (GBG 44). Cancer Res 2009, 69(Suppl.):24. [Abstr 1096].
47. Bear H.D., Tang G., Rastogi P., et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol 2011, 29(Suppl.). [Abstr LBA1005].
48. von Minckwitz G., Eidtmann H., Rezai M., et al. Neoadjuvant Chemotherapy with or without Bevacizumab: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44). Cancer Res 2010, 70(Suppl.):24. [Abstr S4-6].
49. von Minckwitz G., Eidtmann H., Loibl S., et al. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011, 22:301-306.
50. Gerber B, Eidtmann H, Rezai M, et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44). J Clin Oncol. 2011;29(Suppl.) [Abstr 1006].
51. Avastin breast Rx trial enrollment halted due to cardiotoxicity cases. Oncology NEWS International. 2009;18. [Accessed 09.09.11]. http://www.cancernetwork.com/display/article/10165/1477328.
52. Miller K.D., O'Neill A., Perez E.A., Seidman A.D., Sledge G.W. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008, 26:520.
53. Morris P.G., Dickler M., McArthur H.L., et al. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009, 27:6117-6123.
54. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol. 2011.
55. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816.
56. Miller K.D., Trigo J.M., Wheeler C., et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005, 11:3369-3376.
57. Dedes K.J., Matter-Walstra K., Schwenkglenks M., et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009, 45:1397-1406.
58. Berenson A. A cancer drug shows promise, at a price that many can't pay. NY Times. 2006. [Accessed 15.02.11]. http://www.nytimes.com/2006/02/15/business/15drug.html.
59. Pollack A. Genentech caps cost of cancer drug for some patients. NY Times. 2006. [Accessed 31.08.11]. http://www.nytimes.com/2006/10/12/business/12drug.html.
60. Lee J.B., Woo O.H., Park K.H., et al. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs 2011, 29:182-188.
61. O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2010;28:1005.
62. O'Shaughnessy J, Romieu G, Dieras V, Byrtek M, Duenne A-A, Miles D. Meta-Analysis of Patients with Triple-Negative Breast Cancer (TNBC) from Three Randomized Trials of First-Line Bevacizumab (BV) and Chemotherapy Treatment for Metastatic Breast Cancer (MBC). Cancer Res. 2011;70(Suppl.):24 [Abstr P6-12-03].
63. Otrock Z.K., Mahfouz R.A., Makarem J.A., Shamseddine A.I. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007, 39:212-220.
64. Cao Y., Liu Q. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis. Adv Cancer Res 2007, 97:203-224.
65. Shibuya M. Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008, 41:278-286.
66. Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007, 13:2825-2830.
67. Miller V.M., Duckles S.P. Vascular actions of estrogens: functional implications. Pharmacol Rev 2008, 60:210-241.
68. Relf M., LeJeune S., Scott P.A., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963-969.
69. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002, 64:993-998.
70. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
71. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
72. Crawford Y., Kasman I., Yu L., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
73. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009, 30:624-630.
74. Ebos J.M.L., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
75. Paez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
76. Steeg P.S. Angiogenesis inhibitors: motivators of metastasis?. Nat Med 2003, 9:822-823.
77. Harbeck N, Chan A, Huinink DT, et al. No clinical evidence for increase in tumour malignant potential in patients (Pts) with metastatic breast cancer (mBC) treated with bevacizumab (BV) and docetaxel (D) in the phase III AVADO study. Cancer Res. 2009;69(Suppl.):24 [Abstr 6086].
78. Bose D., Meric-Bernstam F., Hofstetter W., Reardon D.A., Flaherty K.T., Ellis L.M. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010, 11:373-382.
79. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878-1886.
80. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000, 105:R15-R24.
81. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 2009, 106:2353-2358.
82. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64:1475-1482.
83. Dellapasqua S., Bertolini F., Bagnardi V., et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905.
84. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
85. Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium. San Antonio, TX, USA 2005.
86. Yardley D.A., Burris H.A., Clark B.L., et al. Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: A phase II trial of the sarah cannon oncology research consortium. Clin Breast Cancer 2011, 11:146-152.
87. Traina T.A., Rugo H.S., Caravelli J.F., et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2010, 28:628-633.
88. Valachis A., Polyzos N.P., Patsopoulos N.A., Georgoulias V., Mavroudis D., Mauri D. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010, 122:1-7.
89. Miles DW, Romieu G, Dieras V, Chen D, Duenne A, O'Shaughnessy J. Meta-analysis of patients previously treated with taxanes from three randomized trials of bevacizumab and first line chemotherpy as treatment for metastatic breast cancer. Ann Oncol. 2010;21:viii97 [Abstr 297PD].
90. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
91. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
92. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678.
93. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
94. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008, 13(Suppl 2):19-21.
95. Oncologic Drugs Advisory Committee. Transcript From Meeting on December 5, 2007. CDER Meeting Documents. 2007. [Accessed 29.08.2011]. http://www.fda.gov/OHRMS/DOCKETS/AC/cder07.htm#OncologicDrugs.
96. US Food and Drug Administration - Center for Drug Evaluation and Research. Memorandum to the File: BLA 125085 Avastin (bevacizumab). 2010. [Accessed 01.06.2011]. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM237171.pdf.
97. Goozner M. Avastin hearing leads to more uncertainty over drug's future. J Natl Cancer Inst 2011, 103:1148-1150.
98. Horning SJ. Post-Hearing Submission of Genentech, Inc. In Support of Maintaining the Accelerated Approval of AVASTIN® (Bevacizumab) in Combination with Paclitaxel for the First-Line Treatment of HER2-Negative Metastatic Breast Cancer - DOCKET NO. FDA-2010-N-0621. 2011. [Accessed 08.09.11]. http://www.cancerletter.com/downloads/20110812_1/download.
99. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer. 2011. [Accessed 17.11.11]. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
100. European Medicines Agency. European public assessment report (EPAR) for Avastin. 2011. [Accessed 17.11.11]. http://www.ema.europa.eu.
101. Verma S., McLeod D., Batist G., Robidoux A., Martins I.R., Mackey J.R. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011, 16:25-35.
102. Saad E.D., Katz A., Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010, 28:1958-1962.
103. Broglio K.R., Berry D.A. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
104. Pegram M., Chan D., Dichmann R., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplifi ed breast cancer. Breast Cancer Res Treat 2006, 100(Suppl.1). [Abstr 301].
105. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
106. Lee K., Qian D.Z., Rey S., Wei H., Liu J.O., Semenza G.L. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 2009, 106:2353-2358.
107. Rapisarda A., Hollingshead M., Uranchimeg B., et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009, 8:1867-1877.
108. Francia G., Cruz-Munoz W., Man S., Xu P., Kerbel R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 2011, 11:135-141.
109. Munoz R., Man S., Shaked Y., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006, 66:3386-3391.
110. Robert N.J., Dieras V., Glaspy J., et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009, 27(Suppl.):15s. [Abstr 1005].